Pixuvri: new option in the treatment of non-Hodgkin's B-cell lymphoma

Pixuvri (pixantrone) is indicated as monotherapy in the treatment of multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma.

The licensed adult dose of pixantrone is 50mg/m2 by intravenous infusion on days 1, 8 and 15 of each 28-day cycle for up to six cycles
The licensed adult dose of pixantrone is 50mg/m2 by intravenous infusion on days 1, 8 and 15 of each 28-day cycle for up to six cycles

PHARMACOLOGY

Pixantrone is a cytotoxic aza-anthracenedione. It has shown minimal cardiotoxicity in animal models compared with doxorubicin or mitoxantrone.1

CLINICAL STUDIES

Salvage treatment

The safety and efficacy of pixantrone were evaluated in a phase III open-label trial involving 140 patients with aggressive non-Hodgkin's lymphoma who had relapsed after two or more previous chemotherapy regimens including at least one standard anthracycline-containing regimen with a response that lasted at least 24 weeks.2

Patients were randomised to receive pixantrone (85mg/m2 by intravenous infusion over one hour on days 1, 8 and 15 of a 28-day cycle for up to six cycles, n=70) or their investigator’s choice of comparator agent at pre-specified standard doses and schedules (n=70).2 Comparator agents included vinorelbine, oxaliplatin, ifosfamide, etoposide, mitoxantrone, gemcitabine and rituximab.2

Complete responses

In the ITT population, significantly more patients achieved a complete or unconfirmed complete response at the end of treatment with pixantrone than with a comparator agent (14 [20%, 95% CI 11.4-31.3] vs 4 [5.7%, 95% CI 1.6-14.0], p=0.021).2

In addition, the overall number of responses (complete, unconfirmed complete or partial) was significantly greater in the pixantrone group than in the comparator group (26 [37.1%, 95% CI 25.9-49.5] vs 10 [14.3%, 95% CI 7.1-24.7]; p=0.003).2  

Median progression-free survival was significantly longer in the pixantrone group than in the comparator group (5.3 months vs 2.6 months, p=0.005).2

Median overall survival was also greater in the pixantrone group than in the comparator group although the difference was not significant.2

Safety profile

The most commonly observed grade 3 or 4 adverse events in the pixantrone group were neutropenia, leucopenia and thrombocytopenia, all of which occurred at a greater rate than in the comparator group.2

The incidence of cardiac adverse events was also higher in the pixantrone group than in the comparator group (35.3% vs 20.9%, respectively); however, these were predominantly asymptomatic grade 1 or 2 declines in left ventricular ejection fraction and did not increase with increasing pixantrone exposure.2


References:

  1. Pixuvri Summary of Product Characteristics, May 2013.
  2. Pettengell R et al. Lancet Oncol 2012; 13: 696–706.

View Pixuvri drug record

Further information: CTI Life Sciences

Follow MIMS on Twitter


Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases